Tonix Pharmaceuticals Holding (STU:TPM0) Research & Development : €67.54 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Tonix Pharmaceuticals Holding's Research & Development for the three months ended in Mar. 2024 was €11.83 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €67.54 Mil.

Tonix Pharmaceuticals Holding Research & Development Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Research & Development Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

16.37

29.72

60.92

77.29

79.46

Tonix Pharmaceuticals Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															24.76	20.28	19.72	15.70	11.83

Tonix Pharmaceuticals Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €67.54 Mil.

Tonix Pharmaceuticals Holding (STU:TPM0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tonix Pharmaceuticals Holding Research & Development Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

TNXP:USA

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines